NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/06/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,933.31 mln
Float127 mln
Earnings Date08/04/2026
EPS
2.21
Solid
P / E
12.87
Fair value
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-1.16
Manipulation likely
1-Year Forecast
33.00
Attractive
Relative Strength
92
/ 100
Top performer
Business Description
ACADIA Pharmaceuticals is a US-based drug development company focused on treating neurological and rare diseases. Its two approved products, NUPLAZID and DAYBUE, address psychosis in Parkinson's disease and symptoms of Rett syndrome respectively. The company has several additional treatments in various stages of clinical trials, targeting conditions such as Alzheimer's disease psychosis, major depressive disorder, essential tremor, and Huntington's disease. Founded in 1993 and based in San Diego, California, ACADIA also works with partners like Neuren Pharmaceuticals and Stoke Therapeutics to expand its pipeline of specialized medicines.
